The effect of molecular weight, PK, and valency on tumor biodistribution and efficacy of antibody-based drugs

Translational Oncology

Volumn 6, Issue 5, 2013, Pages 562-572

  Muchekehu, Ruth ^a   Liu, Dingguo ^a   Horn, Mark ^a   Campbell, Lioudmila ^a   Del Rosario, Joselyn ^a   Bacica, Michael ^a   Moskowitz, Haim ^a   Osothprarop, Trina ^a   Dirksen, Anouk ^a   Doppalapudi, Venkata ^a   Kaspar, Allan ^a   Pirie Shepherd, Steven R ^a   Coronella, Julia ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CVX 2000; FIBROBLAST GROWTH FACTOR RECEPTOR 4; IMMUNOGLOBULIN F (AB') 2 FRAGMENT; IMMUNOGLOBULIN F (AB) FRAGMENT; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TUMOR LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; MALE; MOLECULAR WEIGHT; MOUSE; NEOPLASM; NONHUMAN; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; TUMOR XENOGRAFT;

EID: 84885795522     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13409     Document Type: Article

References (38)

1. Tunggal JK, Cowan DS, Shaikh H, and Tannock IF (1999). Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin Cancer Res 5, 1583-1586.
2. Sedlacek HH, Seemann G, Hoffmann D, Czech J, Lorenz P, Kolar C, and Bosslet K (1992). Antibodies as carriers of cytotoxicity. In Contributions to Oncology. Vol 43. H Huber and W Queiber (Eds). Karger, Basel, Switzerland, pp. 74-75.
3. Ackerman ME, Pawlowski D, and Wittrup KD (2008). Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Mol Cancer Ther 7, 2233-2240.
4. Chaplin DJ, Olive PL, and Durand RE (1987). Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res 47, 597-601.
5. Heldin CH, Rubin K, Pietras K, and Ostman A (2004). High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 4, 806-813.
6. Jain RK (1994). Barriers to drug delivery in solid tumors. Sci Am 271, 58-65.
7. Saga T, Neumann RD, Heya T, Sato J, Kinuya S, Le N, Paik CH, and Weinstein JN (1995). Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci USA 92, 8999-9003.
8. Fujimori K, Covell DG, Fletcher JE, and Weinstein JN (1989). Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab)2, and Fab in tumors. Cancer Res 49, 5656-5663.
9. Teillaud JL (2012). From whole monoclonal antibodies to single domain antibodies: think small. Methods Mol Biol 911, 3-13.
10. Kim SJ, Park Y, and Hong HJ (2005). Antibody engineering for the development of therapeutic antibodies. Mol Cells 20, 17-29.
11. Minchinton AI and Tannock IF (2006). Drug penetration in solid tumours. Nat Rev Cancer 6, 583-592.
12. Thurber GM, Zajic SC, and Wittrup KD (2007). Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med 48, 995-999.
13. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, and Marks JD (1998). Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 77, 1405-1412.
14. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, and Weiner LM (2001). High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61, 4750-4755.
15. Nelson AL (2010). Antibody fragments: hope and hype. MAbs 2, 77-83.
16. Yokota T, Milenic DE, Whitlow M, and Schlom J (1992). Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52, 3402-3408.
17. Nielsen UB, Adams GP, Weiner LM, and Marks JD (2000). Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res 60, 6434-6440.
18. Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, Nagy-Davidescu G, Dreier B, Schibli R, Binz HK, Waibel R, et al. (2010). Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 70, 1595-1605.
19. Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF III, Houston LL, Huston JS, and Weiner LM (2006). Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 12, 1599-1605.
20. Huang H, Lai JY, Do J, Liu D, Li L, Del Rosario J, Doppalapudi VR, Pirie-Shepherd S, Levin N, Bradshaw C, et al. (2011). Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin Cancer Res 17, 1001-1011.
21. Blumenthal RD, Fand I, Sharkey RM, Boerman OC, Kashi R, and Goldenberg DM (1991). The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study. Cancer Immunol Immunother 33, 351-358.
22. Rader C, Turner JM, Heine A, Shabat D, Sinha SC, Wilson IA, Lerner RA, and Barbas CF (2003). A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy. J Mol Biol 332, 889-899.
23. Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, Desharnais J, Hagen C, Levin NJ, Shields MJ, et al. (2010). Chemical generation of bispecific antibodies. Proc Natl Acad Sci USA 107, 22611-22616.
24. Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, Loo HL, Aung MO, Lim SG, and Ullrich A (2009). Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 50, 118-127.
25. Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, and Adams GP (2011). Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors. Cancer Res 71, 2250-2259.
26. Lin BC, Wang M, Blackmore C, and Desnoyers LR (2007). Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 282, 27277-27284.
27. Yu SJ, Zheng L, Ladanyi M, Asa SL, and Ezzat S (2004). Sp1-mediated transcriptional control of fibroblast growth factor receptor 4 in sarcomas of skeletal muscle lineage. Clin Cancer Res 10, 6750-6758.
28. Fleuren ED, Versleijen-Jonkers YM, Heskamp S, Roeffen MH, Bouwman WH, Molkenboer-Kuenen JD, van Laarhoven HW, Oyen WJ, Boerman OC, and van der Graaf WT (2013). The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab)-R1507 fragments in Ewing sarcomas. Eur J Cancer, E-pub ahead of print.
29. Sandström K, Haylock AK, Spiegelberg D, Qvarnström F, Wester K, and Nestor M (2012). A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio. Int J Oncol 40, 1525-1532.
30. Wittrup KD, Thurber GM, Schmidt MM, and Rhoden JJ (2012). Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol 503, 255-268.
31. Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, and Park JW (2005). Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 65, 11631-11638.
32. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, and Park JW (2006). Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66, 6732-6740.
33. Sands H, Jones PL, Shah SA, Palme D, Vessella RL, and Gallagher BM (1988). Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts. Cancer Res 48, 188-193.
34. Dvorak HF, Nagy JA, Dvorak JT, and Dvorak AM (1988). Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133, 95-109.
35. Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, and Marks JD (2012). Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies. Mol Cancer Ther 11, 1467-1476.
36. Kyriakos RJ, Shih LB, Ong GL, Patel K, Goldenberg DM, and Mattes MJ (1992). The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res 52, 835-842.
37. Mayor S, Rothberg KG, and Maxfield FR (1994). Sequestration of GPIanchored proteins in caveolae triggered by cross-linking. Science 264, 1948-1951.
38. Lin BC and Desnoyers LR (2012). FGF19 and cancer. Adv Exp Med Biol 728, 183-194.